Teva Pharmaceutical ADR had its Relative Strength (RS) Rating upgraded from 67 to 72 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matched up against all other stocks.
Over 100 years of market history reveals that the best stocks often have an RS Rating of over 80 in the early stages of their moves. See if Teva Pharmaceutical ADR can continue to rebound and hit that benchmark.
Teva Pharmaceutical ADR is working on a cup without handle with a 22.80 entry. See if it can break out in volume at least 40% higher than normal.
Teva Pharmaceutical ADR reported 8% earnings growth in its most recent report, while sales growth came in at 0%.
The company holds the No. 4 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
